Влияние расовой принадлежности на тактику применения вмешательств, направленных на профилактику развития осложнений сердечно-сосудистых заболеваний

Авторы: Гиляревский С.Р., Голшмид М.В.
Описание:

Различие в рекомендуемых максимальных суточных дозах препаратов назначаемых для профилактики сердечно-сосудистых заболеваний может быть существенным, достигая в некоторых случаях четырехкратного различия. Очевидно, что в некоторых случаях такое различие может быть обусловлено так называемыми «внутренними» факторами. Считается, что международные различия рекомендуемых доз могут быть обусловлены результатами клинических исследований, в ходе которых были установлены этнические различия фармакокинетических и фармакодинамических характеристик.


Влияние мероприятий по изменению факторов риска на риск развития артериальной гипертонии у жителей запанных стран и жителей Восточной Азии

Изменение образа жизни относится к основным подходам к профилактике развития артериальной гипертонии, которая, в свою очередь, представляет собой один из надежных прогностических факторов риска развития осложнений сердечно-сосудистых заболеваний (ССЗ) [1, 2]. Известно, что у жителей стран Азии по сравнению с жителями западных стран сильнее связь между уровнем артериального давления (АД) и риском развития инсульта [3, 4]. 



Для получения доступа к полной статьи необходимо войти или зарегистрироваться
Данный материал предназначен для специалистов и врачей.


Список литературы:

1.      Kokubo Y., Kamide K., Okamura T. et al. Impact of high-normal blood pressure on the risk of cardiovascular disease in a Japanese urban cohort: the Suita study. Hypertension. 2008;52:652—659.

2.      Hozawa A. Attributable fractions of risk factors for cardiovascular diseases. J Epidemiol 2011;21:81—86.

3.      Lawes C.M., Rodgers A., Bennett D.A. et al. Asia Pacific Cohort Studies Collaboration. Blood pres- sure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003;21:707—716.

4.      Woodward M., Barzi F., Martiniuk A. et al. Asia Pacific Cohort Studies Collaboration. Cohort profile: the Asia Pacific Cohort Studies Collaboration. Int J Epidemiol 2006;35:1412—1416.

5.      Perkovic V., Huxley R., Wu Y. et al. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 2007;50:991—997.

6.      Rapsomaniki E., Timmis A., George J. et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet 2014;383:1899—1911.

7.      Martiniuk A.L., Lee C.M., Lawes C.M. et al. Asia-Pacific Cohort Studies Collaboration. Hypertension: its prevalence and population- attributable fraction for mortality from cardiovascular disease in the Asia- Pacific region. J Hypertens 2007;25:73—79.

8.      Chobanian A.V., Bakris G.L., Black H.R. et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206—1252.

9.      Mancia G., Fagard R., Narkiewicz K. et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281—1357.

10.    Liu L.S. Writing Group of 2010 Chinese Guidelines for the Management of Hypertension. 2010 Chinese guidelines for the management of hyper- tension. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39:579—615.

11.    Ogihara T., Kikuchi K., Matsuoka H. et al. Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009;32:3—107.

12.    Goldstein L.B., Bushnell C.D., Adams R.J. et al. American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council for High Blood Pressure Research, Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the primary prevention of stroke: a guideline for healthcare profession- als from the American Heart Association/American Stroke Association. Stroke 2011;42:517—584.

13.    European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008 Cerebrovasc Dis 2008;25:457—507.

14.    Kokubo Y. Prevention of hypertension and cardiovascular diseases: a comparison of lifestyle factors in Westerners and East Asians. Hypertension 2014;63:655—660.

15.    Lloyd-Jones D.M., Larson M.G., Leip E.P. et al. Lifetime risks for developing congestive heart failure: the Framingham Heart Study. Circulation 2002;106:3068—3072.

16.    Bleumink G.S., Knetsch A.M., Sturkenboom M.C. et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004;25:1614—1619.

17.    Schocken D.D., Benjamin E.J., Fonarow G.C. et al. American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; Functional Genomics and Translational Biology Interdisciplinary Working Group: Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008;117:2544—2565.

18.    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7—22.

19.    Ridker P.M., Danielson E., Fonseca F.A. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195—2207.

20.    Baigent C., Blackwell L., Emberson J. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670—1681.

21.    Mihaylova B., Emberson J., Blackwell L. et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581—590.

22.    Malik S., Lopez V., Chen R. et al. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract 2007;77:126—133.

23.    Kotseva K., Wood D., De Backer G. et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373:929—940.

24.    Hermans M.P., Castro Cabezas M., Strandberg T. et al. Centralized Pan-European survey on the undertreatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin 2010;26:445—454.

25.    Waters D.D., Brotons C., Chiang C.W. et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009;120:28—34.

26.    Kim H.S., Wu Y., Lin S.J., et al. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY- Asia) study. Curr Med Res Opin 2008;24:1951—1963.

27.    Park J.E., Chiang C.E., Munawar M. et al. Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. Eur J Prev Cardiol 2012;19:781—794.

28.    Wang K.-F., Chang C.-C., Wang K.-L. et al. Determinants of low-density lipoprotein cholesterol goal attainment: Insights from the CEPHEUS Pan-Asian Survey. J. Chinese Med. Assoc 2014;77;61—67.

29.    Arnold F.L., Kusama M., Ono S. Exploring Differences in Drug Doses Between Japan and Western CountriesClinic Pharmacol Therapeutics 2010;87:714—720.

30.    Kim K., Johnson J.A., Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J. Clin. Pharmacol 2004;44:1083—1105.

31.    Dorne J.L. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation. Fundam. Clin. Pharmacol 2004;18:609—620.

32.    Sekino H., Onishi T. Phase I study of ZD4522 (rosuvastatin), a new HMG-CoA reductase inhibitor— evaluation of tolerance and pharmacokinetics in healthy adult male volunteers after single and repeated oral administration. J Clin Ther Med 2005;21:187—203.

33.    Warwick M.J., Dane A.L., Raza A., Schneck D.W. Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522 [abstract]. Atherosclerosis 2000;151:39.

34.    Martin P.D., Mitchell P.D., Schneck D.W. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol 2002;54:472—477.

35.    Tzeng T., Mitchell P., Zhang H. et al. Population pharmacokinetics of rosuvastatin in normal subjects and subjects with dyslipidemia [abstract]. Clin Pharmacol Ther 2004;75:P56.

36.    Lee E., Ryan S., Birmingham B. et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005;78:330—341.

37.    Saito Y. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag 2009;5:921—936.

38.    Kurihara Y., Douzono T., Kawakita K. et al. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO tablet): LIVALO Effectiveness and Safety (LIVES) Study. Jpn Pharmacol Ther 2008;36:709—731.

39.    Warrington S., Nagakawa S., Hounslow N. Comparison of the Pharmacokinetics of Pitavastatin by Formulation and Ethnic Group. An Open-Label, Single-Dose, Two-Way Crossover Pharmacokinetic Study in Healthy Caucasian and Japanese Men. Clin Drug Investig 2011;31;10:735—743.

40.    Saito Y. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag 2009;5:921—936.

41.    Ose L., Budinski D., Hounslow N., et al. Comparison of pitavas- tatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 2009; 25: 2755—2764.

42.    Yokote K., Bujo H., Hanaoka H. et al. Multicenter colla- borative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis pre- vention (CHIBA study). Atherosclerosis 2008; 201: 345-52.

43.    Hiro T., Kimura T., Morimoto T. et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome] study). J Am Coll Cardiol 2009;54:293—302.


Читать еще


Вход в личный кабинет
Восстановление пароля